CorMedix Reports Q3 2026 Results Amid DefenCath Pricing Transition and Heron Therapeutics Acquisition Plans

CorMedix (CRMD) reported third-quarter 2026 consolidated revenue of $54.5 million, a decrease from $104.3 million in the prior year period. This decline was primarily driven by lower net pricing for DefenCath as it transitioned to a post-TDAPA reimbursement period. Despite this, outpatient dialysis customer utilization remained steady, and the company benefited from a $5 million favorable adjustment regarding Medicaid rebates and product return allowances. The company is pivoting toward diversification through the planned acquisition of Heron Therapeutics assets, which are expected to contribute between $125 million and $150 million in pro forma revenue for 2027. Management anticipates achieving $45 million to $60 million in annualized operating cost synergies by the end of 2027. With $355.2 million in cash and cash equivalents, CorMedix maintains significant liquidity to fund this acquisition and its ongoing operations.

9 articles from 3 sources · updated

Coverage